Self inhibition of phagocytosis: the affinity of 'marker of self' CD47 for SIRPalpha dictates potency of inhibition but only at low expression levels.
about
Calreticulin is the dominant pro-phagocytic signal on multiple human cancers and is counterbalanced by CD47Erythrocyte membrane-camouflaged polymeric nanoparticles as a biomimetic delivery platformTherapeutic opportunities for targeting the ubiquitous cell surface receptor CD47Vascular targeting of nanocarriers: perplexing aspects of the seemingly straightforward paradigmCD47 deficiency in tumor stroma promotes tumor progression by enhancing angiogenesis.Surface functionalization of gold nanoparticles with red blood cell membranesThe effect of CD47 modified polymer surfaces on inflammatory cell attachment and activation.CD47 Enhances In Vivo Functionality of Artificial Antigen-Presenting CellsSIRPα/CD172a and FHOD1 are unique markers of littoral cells, a recently evolved major cell population of red pulp of human spleen.Macrophage engulfment of a cell or nanoparticle is regulated by unavoidable opsonization, a species-specific 'Marker of Self' CD47, and target physical properties.Diminished adhesion and activation of platelets and neutrophils with CD47 functionalized blood contacting surfaces.Disruption of SIRPα signaling in macrophages eliminates human acute myeloid leukemia stem cells in xenografts.Cleavage of Signal Regulatory Protein α (SIRPα) Enhances Inflammatory Signaling.A method for time-resolved measurements of the mechanics of phagocytic cupsBiomimetic delivery with micro- and nanoparticles'Marker-of-self' functionalization of nanoscale particles through a top-down cellular membrane coating approach.Symmetry Controlled, Genetic Presentation of Bioactive Proteins on the P22 Virus-like Particle Using an External Decoration Protein.Immunoenrichment microwave and magnetic proteomics for quantifying CD47 in the experimental autoimmune encephalomyelitis model of multiple sclerosis.Anti-CRLF2 Antibody-Armored Biodegradable Nanoparticles for Childhood B-ALLThe use of CD47-modified biomaterials to mitigate the immune response.Intracellular signaling mechanisms associated with CD47 modified surfaces.Lipid-insertion enables targeting functionalization of erythrocyte membrane-cloaked nanoparticles.Liposome-like Nanostructures for Drug Delivery."Marker of Self" CD47 on lentiviral vectors decreases macrophage-mediated clearance and increases delivery to SIRPA-expressing lung carcinoma tumorsArtificial cells: from basic science to applications.Interfacial interactions between natural RBC membranes and synthetic polymeric nanoparticles.Inspired by nature: fundamentals in nanotechnology design to overcome biological barriers.CD47 in Erythrocyte Ageing and Clearance - the Dutch Point of View.Red blood cell clearance in inflammation.Merging the best of both worlds: hybrid lipid-enveloped matrix nanocomposites in drug delivery.Polymeric nanotherapeutics: clinical development and advances in stealth functionalization strategies.Impact of elastic and inelastic substrate behaviors on mechanosensation.Mechanisms of Immune Tolerance in Leukemia and Lymphoma.Gambogic acid-loaded biomimetic nanoparticles in colorectal cancer treatment.Erythrocytes in nanomedicine: an optimal blend of natural and synthetic materials.Mimicking biological functionality with polymers for biomedical applications.Cell membrane-derived nanomaterials for biomedical applications.Bio-inspired nanomedicine strategies for artificial blood components.How do red blood cells know when to die?Study of the D-- phenotype reveals erythrocyte membrane alterations in the absence of RHCE.
P2860
Q24561405-E8C8B6C9-B35B-4690-9BBA-297CDC19DBDCQ24596232-3A8029C2-71CA-4A9C-AF07-938C5D91D9FEQ24627155-64C1377B-A84F-45DA-8FD2-C71C042A747CQ27026630-E495BA88-607A-4861-826F-6219A59146D3Q33618348-336C8728-3D5D-46EE-9EE4-B135024F4477Q34067202-38B36FBD-97A8-45A7-B614-728725EC8F7EQ35024822-331DA19A-CFC5-43AF-8EDE-CF7ADAE00A91Q35563107-03FB82D1-8ECF-4BA5-8783-67E5286DDF7AQ35903177-07C05C92-763B-4BA2-9FD5-00916E0CD5D6Q36005980-FA03741E-D673-4DE4-B5BF-73A3A0E1FD23Q36010745-1C312E91-30A7-4DDB-94B1-800937158B48Q36278046-44361773-4ACB-49D8-8418-BBF5F1122D9EQ36407323-51D50782-7F56-4A51-BCD5-8DB857E6825CQ36767910-5F0F2B2F-3894-458E-B4A3-145448E68377Q36768786-B876328A-5538-427C-BCC1-5FD51AE17DC8Q36886925-110D1677-3ECD-483D-AB55-DAE33A434C75Q36892485-E5477538-077A-4FA2-8935-55D780B1A5ACQ37047855-66E1ACC3-6404-4BA5-92A2-F9E359E527A3Q37102970-B5B21913-41A4-447C-973F-F3991356C47EQ37107151-5A864908-5DA2-4AF2-B013-601862BFD233Q37244592-666A7444-38C0-4D6B-8F5A-445377DA838EQ37316779-0978B028-B919-4F82-9E13-20C0E0B3A4E6Q37424654-6A434D30-D799-4EA9-BF09-0BF663D4352AQ37490583-1E59A7BD-599E-4260-83C6-6746A39B6454Q37574221-B82E3CFE-67AC-4C90-BB07-4FED3B5BED9AQ37638568-E19F79B6-35D4-4C55-A344-5CA8CC376B21Q38074461-AFFA5586-C57B-45B5-86FC-44AB33028854Q38117134-1DFAEB1A-1752-4FDB-A99E-36751D045E51Q38117135-205713AB-F437-42C2-A6BA-FDF63EA6D52DQ38150118-BDE95A48-31A4-48D4-AB7E-1623E7E171D1Q38166550-DDCC97D9-E213-48E3-86D3-EE9928F88DB8Q38197922-DDE255D8-EAEB-4005-A810-A357BCAF3CE6Q38683034-04725F4E-AD00-421C-9730-39D3CEE9F0F2Q38712865-5203F431-1246-4574-8CD2-A2AA93CD9816Q38811159-D9158311-64C8-4F18-BBCB-6D7F73EF86C2Q39038679-9153AD13-2B52-44CF-B581-24F9642E4008Q39178313-D8AB664F-60A8-41D1-B4D5-32B549508FDAQ39179984-944F2E2B-EDF4-4E52-9A30-758B6497548AQ41917616-D2C57EB2-CA4D-487D-9CE3-F95955F6CB44Q44944017-97AD5E25-29F2-4826-AFD9-97781902A0D5
P2860
Self inhibition of phagocytosis: the affinity of 'marker of self' CD47 for SIRPalpha dictates potency of inhibition but only at low expression levels.
description
2010 nî lūn-bûn
@nan
2010年の論文
@ja
2010年論文
@yue
2010年論文
@zh-hant
2010年論文
@zh-hk
2010年論文
@zh-mo
2010年論文
@zh-tw
2010年论文
@wuu
2010年论文
@zh
2010年论文
@zh-cn
name
Self inhibition of phagocytosi ...... only at low expression levels.
@en
Self inhibition of phagocytosi ...... only at low expression levels.
@nl
type
label
Self inhibition of phagocytosi ...... only at low expression levels.
@en
Self inhibition of phagocytosi ...... only at low expression levels.
@nl
prefLabel
Self inhibition of phagocytosi ...... only at low expression levels.
@en
Self inhibition of phagocytosi ...... only at low expression levels.
@nl
P2860
P1476
Self inhibition of phagocytosi ...... only at low expression levels
@en
P2093
Pia L Rodriguez
Richard K Tsai
P2860
P356
10.1016/J.BCMD.2010.02.016
P577
2010-03-17T00:00:00Z